Skaana Management L.P. Novavax Inc Call Options Transaction History

Skaana Management L.P.

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$10.71 - $17.11 $447,678 - $715,198	-41,800 Reduced 89.51%	4,900 $61,000
Q2 2024 Jul 31, 2024	SELL	$3.89 - $20.97 $544,989 - $2.94 Million	-140,100 Reduced 75.0%	46,700 $591,000
Q1 2024 May 14, 2024	BUY	$3.76 - $6.02 $122,200 - $195,650	32,500 Added 21.06%	186,800 $892,000
Q4 2023 Feb 14, 2024	BUY	$4.8 - $7.67 $374,400 - $598,260	78,000 Added 102.23%	154,300 $740,000
Q3 2023 Nov 14, 2023	SELL	$6.81 - $9.74 $14,982 - $21,428	-2,200 Reduced 2.8%	76,300 $552,000
Q2 2023 Aug 14, 2023	SELL	$6.67 - $9.52 $127,397 - $181,832	-19,100 Reduced 19.57%	78,500 $583,000
Q1 2023 May 15, 2023	BUY	$5.76 - $12.48 $562,176 - $1.22 Million	97,600 New	97,600 $676,000

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $620M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Skaana Management L.P., based on Form 13F filings with the SEC.

Stay updated on Skaana Management L.P. with notifications on news.